AIMS & OBJECTIVES:

Aim: - To enhance the solubility and bioavailability of Eprosartan mesylate by solid dispersion technique.

To accomplish above mentioned aim following objectives is to be employed

Eprosartan Mesylate is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist. Eprosartan (1200 mg once daily for 7 days or 300 mg twice daily for 28 days) had no effect on the excretion of uric acid in healthy men, patients with essential hypertension or those with varying degrees of renal insufficiency. There were no effects on mean levels of fasting triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol or fasting glucose.

1) It is BCS class II drug, It exhibit slow and erratic absorption through GIT
2) Increase drug bioavailability.
3) Reducing potential toxicities and accumulation of drug in unwanted tissues / organs
4) Intentions to develop strategies and designing delivery systems meeting ideal conditions.
5) To overcome drawbacks due to poor bioavailability , large amount of drug from its dose excreted unchanged from the body organs.
6) To justify in improvement in the rate and extent of dissolution.
7) To select and compare effectiveness of hydrophilic polymers for dissolution rate improvement.
8) To study effect of process parameter.